TransDigm Group Incorporated Form 4 Filings

For TransDigm Group INC (TDG), Co-Chief Operating Officer Joel Reiss reported an option exercise and related share sales. On August 17, 2026 he exercised 3,900 stock options at a strike price of $284.97 per share, acquiring 3,900 shares of common stock. That same day he sold 3,900 common shares in multiple open-market transactions at weighted-average prices ranging from about $1,232.28 to $1,253.55 per share. Following the exercise, he held 8,000 stock options for TransDigm common stock. The filing indicates these transactions were made under a Rule 10b5-1 trading plan.

TransDigm Group executive Joel Reiss, Co-Chief Operating Officer, reported exercising stock options covering 3,900 shares of common stock on July 15, 2026 at an exercise price of $284.97 per share, leaving 11,900 options outstanding. The amended filing corrects the coding of this derivative transaction from an acquisition to a disposition and indicates it was effected under a Rule 10b5-1 trading plan.

TransDigm Group director W. Nicholas Howley reported that his family trust exercised 10,132 stock options for common stock on 2026-07-20 at an exercise price of $66.4700 per share, leaving 11,832 options indirectly held. The trust received 10,132 common shares, then sold 10,132 shares in multiple sale transactions, including 570 shares at $1,210.3242 and 440 shares at $1,224.1377 per share. The filing indicates these transactions were executed under a Rule 10b5-1 trading plan.

TransDigm Group’s Co-Chief Operating Officer Joel Reiss reported selling 414 shares of common stock on July 15, 2026 in multiple open-market or private transactions at prices between $1,229.6600 and $1,233.3800 per share, pursuant to a Rule 10b5-1 trading plan.

TransDigm Group Co-Chief Operating Officer Joel Reiss exercised stock options for 3,900 common shares at $284.97 per share and sold 3,486 shares of common stock on July 15, 2026, in multiple open market or private transactions carried out under a Rule 10b5-1 trading plan.

After these transactions, he directly holds 4,014 TransDigm common shares and 19,700 stock options with a $284.97 exercise price expiring on November 8, 2027.

TransDigm Group director W. Nicholas Howley reported an amended insider filing reflecting an “other” type transaction with no change in share ownership. The filing shows 0 common shares were transacted and 21,547.513 shares are held indirectly through the W. Nicholas Howley Family Trust u/a/d 4/23/99.

TransDigm Group director W. Nicholas Howley, through his family trust, reported an exercise-and-sell transaction in company stock. On June 18, 2026, the W. Nicholas Howley Family Trust exercised 10,132 stock options at an exercise price of $66.47 per share and acquired the same number of common shares.

The trust then sold 10,132 shares of TransDigm common stock in multiple open-market trades, at prices ranging from approximately $1,305 to $1,337.06 per share. Following these transactions, the trust’s indirect holdings in TransDigm common stock were 21,547.513 shares.

TransDigm Group INC director W. Nicholas Howley reported coordinated option exercises and share sales through his family trust. On June 18, 2026, the W. Nicholas Howley Family Trust u/a/d 4/23/99 exercised stock options for 10,132 shares of TransDigm common stock at an exercise price of $66.47 per share and sold 10,132 common shares in multiple open-market transactions.

The reported sale prices ranged around $1,305–$1,337 per share, with each line item giving a weighted average price for trades within a specific band. Following these transactions, the trust indirectly holds 21,547.513 shares of TransDigm common stock.

TransDigm Group director W. Nicholas Howley, through the W. Nicholas Howley Family Trust, reported an option exercise and related stock sales in TransDigm Group INC common stock. On June 18, the trust exercised options to acquire 10,132 shares at an exercise price of $66.47 per share.

That same day, the trust executed multiple open‑market sales totaling 10,132 shares of common stock at prices generally around $1,305 to $1,337 per share, as detailed in the reported weighted‑average price ranges. The transactions together represent an exercise‑and‑sell pattern carried out through the family trust’s indirect ownership.

TransDigm Group reports that Co-Chief Operating Officer Joel Reiss exercised 3,900 stock options at $284.9700 per share into common stock on June 15, 2026, then sold 3,900 common shares in multiple trades at prices within $1,268.6100–$1,288.0400 per share. Following these transactions, he directly holds 3,600 common shares.

TransDigm Group director W. Nicholas Howley, through the W. Nicholas Howley Family Trust u/a/d 4/23/99, reported an exercise-and-sell transaction in TransDigm common stock. On 2026-05-18, the trust exercised stock options for 10,132 shares at an exercise price of $66.47 per share and sold 10,132 common shares in a series of open-market trades at prices around $1,160–$1,189 per share. Following these transactions, the filing shows indirect ownership of 21,547.513 TransDigm common shares by the trust.

TransDigm Group INC Co-Chief Operating Officer Joel Reiss exercised 3,900 stock options at a strike price of $284.97 per share into common stock on May 15, 2026, then sold 3,900 common shares in 27 reported trades at weighted-average prices, with footnotes noting execution ranges from about $1,143.72 to $1,175.31 per share under a Rule 10b5-1 trading plan. Following these transactions, he directly holds 3,600 shares of TransDigm common stock.

TransDigm Group Inc. director W. Nicholas Howley, through the W. Nicholas Howley Family Trust u/a/d 4/23/99, reported an exercise-and-sell sequence in TransDigm common stock. The trust exercised stock options for 10,132 shares at exercise prices of $66.47 and $50.92 per share.

On the same date, the trust completed multiple open-market sales totaling 10,132 shares at per-share prices generally around $1,260–$1,272, reported as weighted averages for several price ranges. Following these transactions, the trust indirectly held 21,547.513 shares of TransDigm common stock.

TransDigm Group’s Co-Chief Operating Officer Joel Reiss exercised stock options for 3,900 shares of common stock at an exercise price of $284.9700 per share and on the same date sold 3,900 shares in multiple open-market transactions at prices ranging from $1,273.8500 to $1,294.8000. Following these transactions, he holds 3,600 shares of TransDigm common stock directly.

Palmer Peter reported acquisition or exercise transactions in this Form 4 filing.

TransDigm Group director Peter Palmer received 30 shares of Common Stock as compensation, valued at $1,214.66 per share, in connection with his semi-annual director fee under the Director Share Plan. Following this stock-in-lieu-of-cash award, he directly holds 4,030 TransDigm Group shares.

TransDigm Group director Jane M. Cronin received a stock grant as board compensation. She acquired 30 shares of TransDigm common stock on March 20, 2026 at a fair market value of $1,214.66 per share, issued in lieu of her semi-annual director fee under the Director Share Plan.

Following this grant, Cronin directly holds 699.62 shares of TransDigm common stock. This is a routine equity compensation award rather than an open‑market share purchase or sale.

HENNESSY SEAN P reported acquisition or exercise transactions in this Form 4 filing.

TransDigm Group director Sean P. Hennessy received 41 shares of common stock as compensation, valued at $1,214.66 per share. This was a stock grant rather than an open-market purchase.

The shares were issued in lieu of his semi-annual director fee under the company’s Director Share Plan, bringing his direct holdings to 33,790.09 shares.

MCCULLOUGH GARY E reported acquisition or exercise transactions in this Form 4 filing.

TransDigm Group Inc. director Gary E. McCullough received 37 shares of common stock as a stock-based director fee. The shares were valued at $1,214.66 per share, reflecting payment of a semi-annual board fee in stock rather than cash under the Director Share Plan. Following this award, he directly holds 952 common shares, indicating a relatively small, routine compensation-related increase in his ownership rather than an open-market purchase.

Santana Michele reported acquisition or exercise transactions in this Form 4 filing.

TransDigm Group INC director Michele Santana received 30 shares of Common Stock as a compensation award. The shares were valued at $1,214.66 each and were issued in lieu of a semi-annual director cash fee, based on fair market value under the company’s Director Share Plan. After this grant, Santana directly holds 771 TransDigm shares, reflecting routine equity-based board compensation rather than an open-market purchase.

BARR DAVID reported acquisition or exercise transactions in this Form 4 filing.

TransDigm Group director David Barr received 41 shares of Common Stock as a grant. The shares were valued at $1,214.66 per share and were issued on March 20, 2026. After this award, Barr directly owns 32,179 shares. A footnote explains the shares were received in lieu of a semi-annual director fee, based on fair market value under the company’s Director Share Plan.

Graff Michael reported acquisition or exercise transactions in this Form 4 filing.

TransDigm Group director Michael Graff received 30 shares of Common Stock as a stock grant on March 20, 2026. The shares were valued at $1,214.66 per share and were issued in lieu of his semi-annual director fee under the company’s Director Share Plan. Following this grant, he holds 1,683 shares directly, plus additional indirect holdings held by family trusts for the benefit of his children.

Howley W Nicholas reported acquisition or exercise transactions in this Form 4 filing.

TransDigm Group director W. Nicholas Howley received 113 shares of Common Stock as a grant on March 20, 2026. The shares were issued at a fair market value of $1,214.66 per share, in lieu of a semi-annual director fee under the Director Share Plan.

After this award, Howley holds 113 shares directly. He also has indirect beneficial holdings of 8,262 shares through The Howley Family Foundation and 21,547.513 shares through the W. Nicholas Howley Family Trust u/a/d 4/23/99, as reported in this filing.

TransDigm Group director W. Nicholas Howley, through the W. Nicholas Howley Family Trust, reported an option exercise and related share sales. The trust exercised stock options for 10,132 shares of TransDigm common stock at an exercise price of $50.9200 per share, converting them into 10,132 common shares.

The trust then sold 10,132 common shares in multiple open-market transactions on the same date at prices ranging from about $1,205.4151 to $1,231.3415 per share. Following these transactions, the trust continues to hold 21,547.513 TransDigm common shares indirectly attributed to Howley.

TransDigm Group’s Co‑Chief Operating Officer Joel Reiss exercised stock options and then sold shares in the open market. He exercised options for 3,900 shares of common stock at an exercise price of $284.97 per share and acquired the underlying shares.

On the same date, he sold 3,900 common shares in a series of transactions at prices around $1,222.87 to $1,250.65 per share, leaving him with 3,600 common shares held directly. Following the option exercise, he also continues to hold 27,500 stock options scheduled to expire on November 8, 2027. This filing reflects a routine exercise‑and‑sell transaction by a senior executive rather than a change in company operations.

TransDigm Group Inc director Robert J. Small reported an indirect open‑market purchase by Stockbridge Fund, L.P. of 1 share of common stock at $1,285.00 per share on February 25, 2026. The filing notes this purchase was matchable under Section 16(b) with a prior sale of 1 share at $1,335.72 per share by an entity in which he has a pecuniary interest, and he paid the issuer the difference between the two prices. Following the transactions reported, indirect holdings include 366,142 shares held by Stockbridge Fund, L.P., 68,139 shares held by Stockbridge Partners LLC, and 60,246 shares held by certain family trusts, plus 5,625 shares held directly.

TransDigm Group’s Co-Chief Operating Officer Patrick Joseph Murphy exercised stock options and acquired common shares. On February 24, 2026, he exercised options for 1,160 shares and 300 shares of TransDigm common stock.

The 1,160 shares were acquired at $269.42 per share and the 300 shares at $347.17 per share through derivative exercises coded as “M.” Following these transactions, Murphy directly owned 2,515 shares of TransDigm common stock.

TransDigm Group Inc. reported insider activity involving a family trust associated with director W. Nicholas Howley. On February 18, 2026, the W. Nicholas Howley Family Trust u/a/d 4/23/99 sold 10,168 shares of TransDigm common stock in a series of open-market transactions. The weighted-average sale prices ranged from about $1,298.96 to $1,312.24 per share across the reported trades.

On the same date, the trust exercised stock options covering 10,168 shares of common stock at an exercise price of $50.92 per share, with the exercise price adjusted for dividends declared since August 1, 2022. After these transactions, the trust held 30,765.513 shares of common stock and 18,040 stock options indirectly.

TransDigm Group Co‑Chief Operating Officer Joel Reiss exercised stock options for 3,900 shares of common stock at an exercise price of $284.97 per share and received the underlying shares on February 17, 2026.

On the same day, he sold 3,900 TransDigm common shares in multiple open‑market transactions at prices generally between about $1,279 and $1,305 per share. After these trades, Reiss directly holds 3,600 shares of common stock and 31,400 stock options.

TransDigm Group president and CEO Michael Lisman bought 950 shares of TransDigm common stock on February 6, 2026 at $1,284.2608 per share, increasing his directly held stake to 3,259 shares. He also beneficially owns 1,954 shares indirectly through the Michael Lisman Declaration of Trust dated January 31, 2023.

A note clarifies that a Form 4 filed on November 14, 2025 mistakenly duplicated the 1,954 trust shares, and confirms that 1,954 is the correct number of shares held indirectly in the trust.

TransDigm Group’s Chief Financial Officer, Sarah Wynne, reported an option exercise and related share acquisition. On 02/05/2026, she exercised stock options for 1,494 shares of common stock at $559.78 per share. Following the transaction, she directly owned 4,894 shares of common stock and 3,506 stock options.

TransDigm Group director Kevin M. Stein, through Fortuna Trust dated June 1, 2018, reported a series of open-market sales of TransDigm common stock on February 2, 2026. The trust sold multiple blocks of shares at average prices ranging from $1,431.4599 to $1,440.4800 per share.

Individual transactions included sales such as 3,093 shares at an average price of $1,433.4578 and 1,497 shares at $1,436.4265. Following these sales, Fortuna Trust was reported as indirectly holding 8,158 TransDigm common shares.

TransDigm Group director-related trust reports option exercises and share sales. On February 2, 2026, Fortuna Trust dated June 1, 2018, an entity associated with director Kevin M. Stein, exercised stock options for 25,000 shares at $341.28 and 23,000 shares at $342.31.

The trust then executed a series of open‑market sales of TransDigm common stock at prices mainly around $1,404–$1,431. Following these transactions, the trust’s indirectly held TransDigm common stock position reported in this filing was 19,233 shares.

TransDigm Group Co-Chief Operating Officer Patrick Joseph Murphy reported an option exercise and share sale. On February 2, 2026, he exercised a stock option for 290 shares of Common Stock at an exercise price of $269.42 per share and acquired these shares.

On the same date, he sold 290 shares of Common Stock at a price of $1,430.1 per share. After these transactions, he beneficially owned 1,055 shares of Common Stock directly and 1,160 stock options directly.

TransDigm Group’s Co-Chief Operating Officer Joel Reiss reported an insider transaction involving stock options and common shares on January 15, 2026. He exercised 3,900 stock options at an exercise price of $284.97 per share, receiving the same number of TransDigm common shares. On the same date, he sold common stock in a series of small trades, each reported with an average weighted sale price, at levels ranging from about $1,420 to $1,439 per share. After these transactions, he directly owned 3,600 shares of TransDigm common stock and 35,300 stock options. The footnotes clarify that each reported sale price is a weighted average, with full price breakdowns available to regulators or shareholders on request.

TransDigm Group director Kevin M. Stein, through Fortuna Trust dated June 1, 2018, reported linked option and share transactions dated January 14, 2026. The trust exercised 7,627 stock options for TransDigm common stock at an exercise price of $342.31 per share, receiving 7,627 shares.

The trust then sold TransDigm common shares in three weighted-average blocks: 2,141 shares at $1,405.6379, 3,964 shares at $1,406.4099, and 1,522 shares at $1,407.3422. After these trades, the trust held 8,158 TransDigm common shares and 43,000 stock options indirectly for the reporting person.

TransDigm Group director Kevin M. Stein, through the Fortuna Trust dated June 1, 2018, reported an option exercise and related stock sales. On January 8, 2026, the trust exercised a stock option for 17,373 shares of common stock at an exercise price of $342.31 per share, with the price adjusted for dividends declared since August 1, 2022. The same day, the trust sold a total of 17,373 TransDigm Group shares in several market transactions at average prices ranging from about $1,405.3006 to $1,413.17 per share. After these transactions, the trust held 8,158 shares of TransDigm common stock and 50,627 stock options, all reported as indirectly owned.

TransDigm Group Inc. director Kevin Stein, through the Fortuna Trust dated June 1, 2018, reported option exercises and share sales dated 01/05/2026. The trust exercised 17,940 stock options at an exercise price of $105.88 per share and another 7,060 options at $341.28 per share, both relating to TransDigm common stock.

On the same date, the trust sold multiple blocks of TransDigm common stock in open-market transactions at prices ranging from about $1,361.59 to $1,387.035 per share, reported as weighted average prices for each sale line. After these transactions, the trust indirectly held 8,158 shares of TransDigm common stock and 42,940 stock options, all reported as indirectly owned through the Fortuna Trust.

TransDigm Group Inc. reported an insider stock transaction by its Co-Chief Operating Officer, Patrick J. Murphy. On 01/02/2026, Murphy exercised a stock option to acquire 290 shares of TransDigm common stock at an exercise price of $269.42 per share. On the same day, he sold 290 shares of common stock at a price of $1,329.03 per share.

After these transactions, Murphy beneficially owned 1,055 shares of TransDigm common stock directly and held 1,450 stock options as derivative securities.

TransDigm Group Inc.’s Co-Chief Operating Officer reported an option exercise and related stock sales. On 12/15/2025, he exercised 3,900 stock options at an exercise price of $284.97 per share and received the same number of TransDigm common shares. The filing then shows multiple open-market sales of TransDigm common stock that day in small blocks at weighted-average prices within ranges from about $1,282.12 to $1,311.40. After these transactions, he directly beneficially owned 3,600 shares of common stock and held 39,200 stock options that remain outstanding.

TransDigm Group Inc. director reports option exercise and share sales. On 12/10/2025, the reporting person exercised a stock option for 4,700 shares of TransDigm common stock at an exercise price of $66.47 per share and acquired those shares. The same day, they sold a total of 4,700 shares in three open market transactions: 580 shares at a weighted average price of $1,289.3197, 4,046 shares at $1,290.2959, and 74 shares at $1,291.0322, leaving 5,625 shares held directly.

The option covered 4,700 shares of common stock, was exercisable beginning 09/30/2018, and was set to expire on 11/08/2027. After these transactions, the reporting person also continues to hold significant indirect ownership, including 366,141 shares through Stockbridge Fund, L.P., 68,139 shares through Stockbridge Partners LLC, and 60,246 shares through family trusts.

TransDigm Group director Robert J. Small reported sales of the company’s common stock in a Form 4 filing. On 12/09/2025, entities associated with him sold 75,673 and 15,280 shares of TransDigm common stock at $1,335.72 per share.

After these transactions, 366,141 shares are held indirectly through Stockbridge Fund, L.P., 68,139 shares through Stockbridge Partners LLC, and 60,246 shares through certain family trusts, with an additional 5,625 shares held directly. The filing states that Small may be deemed to share voting and dispositive power over these holdings but disclaims beneficial ownership beyond any pecuniary interest.

TransDigm Group Inc. reported an insider stock transaction involving a company director. A stock option for 17,526 shares of common stock with an exercise price of $105.88 was exercised on 12/04/2025 and held indirectly through the Fortuna Trust dated June 1, 2018.

The trust then reported a series of open-market sales of TransDigm common stock on the same date at weighted average prices ranging from about $1,360.0000 to $1,367.2300 per share. After these transactions, the trust held 8,158 shares of TransDigm common stock and 37,940 derivative securities beneficially owned. The filing notes that the reported sale prices are weighted averages and that full price breakdowns for each trade within the ranges are available upon request.

TransDigm Group Inc. insider transaction: A company officer serving as Co‑Chief Operating Officer reported an option exercise and related stock sale. On 12/01/2025, the insider exercised a stock option to acquire 290 shares of TransDigm common stock at an exercise price of $269.42 per share, then on the same date sold 290 shares of common stock at a price of $1,351.06 per share.

After these transactions, the insider directly beneficially owned 1,055 shares of TransDigm common stock and 1,740 stock options. The filing was made as a Form 4 by one reporting person, reflecting routine insider equity activity.

TransDigm Group Inc. filed a Form 4 reporting equity transactions by director Kevin Stein through the Fortuna Trust dated June 1, 2018. On 11/28/2025, the trust exercised a stock option for 4,592 shares of TransDigm common stock at an exercise price of $105.88 per share. The option relates to an award originally exercisable from 09/30/2018 and expiring on 04/25/2028, and its exercise price has been adjusted for dividends declared since August 1, 2022.

On the same date, the trust reported sales of TransDigm common stock in three transactions of 2,997, 1,545 and 50 shares at volume-weighted average prices of approximately $1,360.44, $1,361.25 and $1,362.43, respectively, within narrow intraday price ranges. Following these transactions, the Fortuna Trust indirectly held 8,158 shares of TransDigm common stock.

TransDigm Group Inc. (TDG) director Kevin Stein, through the Fortuna Trust dated June 1, 2018, reported stock option exercises and related share sales. On 11/25/2025, the trust exercised 4,187 stock options at an exercise price of $105.88 per share and then sold 4,097 common shares at a weighted average price of $1,360.5495 per share, plus an additional 90 shares at a weighted average price of $1,361.8702 per share. On 11/26/2025, the trust exercised another 30 stock options at $105.88 per share and sold 30 shares at $1,360.06 per share. After these transactions, the trust beneficially owned 8,158 TDG common shares and 60,058 stock options indirectly.

TransDigm Group Inc. (TDG) director Michael Graff reported a gift of 340 shares of common stock on 11/21/2025, as shown on this Form 4. The transaction, coded "G" for gift, was at a reported price of $0 per share.

After this transaction, Graff directly owns 1,653 TransDigm common shares. He also reports indirect ownership of 5,096 shares held by The 2012 Carol Ostrow GST Trust created by his spouse for their children, and 7,000 shares held by certain other trusts created for the benefit of their children, for which he serves as trustee.

TransDigm Group (TDG) director Form 4 shows an option exercise and matching share sale by an affiliated trust. On 11/21/2025, the Fortuna Trust dated June 1, 2018 exercised 230 stock options for TransDigm common stock at an exercise price of $105.88 per share and acquired 230 shares. The trust then sold 230 common shares at an average price of $1,360.3096 per share, leaving it with 8,158 shares of indirect beneficial ownership. Following the transaction, the trust continues to hold 64,275 stock options indirectly, with an exercise price of $105.88 and an expiration date of 04/25/2028.

TransDigm Group (TDG) director Kevin Stein, reporting through the Fortuna Trust dated June 1, 2018, disclosed an option exercise and related share sales. On 11/20/2025, the trust exercised a stock option for 1,104 shares of common stock at an exercise price of $105.88 per share, originally granted in 2018 and expiring in 2028. The same day, the trust sold 655 shares at an average $1,360.3298, 400 shares at an average $1,361.5239, and 49 shares at an average $1,363.2231, with each sale reported as an average weighted price over a narrow range. After these transactions, the trust beneficially owned 8,158 shares of TransDigm common stock and 64,505 stock options, all reported as indirect ownership through the trust.

TransDigm Group Inc. (TDG) director Kevin Stein reported an option exercise and related share sales on 11/18/2025, all held indirectly through the Fortuna Trust dated June 1, 2018. A stock option for 7,191 shares of common stock was exercised at an adjusted price of $105.88 per share.

The shares acquired on exercise were then sold in multiple open-market transactions the same day, using weighted-average prices, with example sales including 3,580 shares at $1,360.2775 and 1,531 shares at $1,362.6356. The filing notes that the exercise price has been adjusted for dividends declared since August 1, 2022. After these transactions, the trust beneficially owns 8,158 shares of TransDigm common stock and 65,609 stock options.